Medical Lymphatic Animation

Earlier, Individualized Treatment Of Thyroid Cancer Enabled By Molecular Imaging
In a study to determine the diagnostic value of molecular imaging in nodal staging of patients with thyroid cancer, researchers were able for the first time to accurately distinguish between cancerous cells in regional lymph nodes and normal residual thyroid tissue directly after surgery.

Study Links Molecule To Muscle Maturation, Muscle Cancer
Researchers at The Ohio State University Comprehensive Cancer Center have discovered that a molecule implicated in leukemia and lung cancer is also important in muscle repair and in a muscle cancer that strikes mainly children. The study shows that immature muscle cells require the molecule, called miR-29, to become mature, and that the molecule is nearly missing in cells from rhabdomyosarcoma, a cancer caused by the proliferation of immature muscle cells.

Grape Seed Extract Kills Cancer Cells In Lab
A team of scientists from the US and China have discovered that grape-seed extract kills laboratory leukemia cells by making them commit suicide, thus showing the potential value of natural compounds in the treatment of cancer.

Grape Seed Extract Kills Laboratory Leukemia Cells, Proving Value Of Natural Compounds
An extract from grape seeds forces laboratory leukemia cells to commit cell suicide, according to researchers from the University of Kentucky. They found that within 24 hours, 76 percent of leukemia cells had died after being exposed to the extract. The investigators, who report their findings in the January 1, 2009, issue of

EU Grants VIDAZA® Full Marketing Authorization For The Treatment Of Patients With Higher-Risk Myelodysplastic Syndromes And Acute Myeloid Leukaemi
Celgene International Sàrl (Nasdaq:CELG) today announced that its cancer drug, VIDAZA (azacitidine), has been granted full marketing authorization by the European Commission for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with: -- I

Paediatric Patient Treated Using RapidArc™ Radiotherapy Technology In Switzerland
A Swiss cancer clinic is among the first in the world to use a new, faster radiotherapy technology from Varian Medical Systems (NYSE: VAR) to treat a child patient. A 12-year-old girl with Hodgkin's lymphoma was treated using Varian's RapidArc™ technique at the Oncology Institute of Southern Switzerland (IOSI) in Bellinzona.

FDA Approves Drug That Boosts Stem Cell Yield For Bone Marrow Transplants
The U.S. Food and Drug Administration approved Mozobil (plerixafor), a drug that helps increase the number of blood stem cells for bone marrow transplantation in patients with certain forms of blood cancer. Mozobil is intended to be used in combination with the growth factor granulocyte-colony stimulating factor (G-CSF), for treatment of adults with multiple myeloma or non-Hodgkin's lymphomas.

EpiCept Announces Health Canada's Approval For Ceplene Filing For The Treatment Of Acute Myeloid Leukemia
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) has announced that, at a recent pre-New Drug Submission (pre-NDS) meeting with representatives of Health Canada, it received permission to proceed with a New Drug Submission (NDS) filing for Ceplene® (histamine dihydrochloride) for the treatment of acute myeloid leukemia (AML) in Canada.

FDA Approves Genzyme's Mozobil - Provides Stem Cell Mobilization For Autologous Transplantation In NHL And Multiple Myeloma Patients
Genzyme Corporation (Nasdaq: GENZ) has announced that the U.S. Food and Drug Administration has granted marketing approval for Mozobil™ (plerixafor injection), a drug intended to be used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).

Stem Cells And Leukemia Battle For Marrow Microenvironment
Learning how leukemia takes over privileged "niches" within the bone marrow is helping researchers develop treatment strategies that could protect healthy blood-forming stem cells and improve the outcomes of bone marrow transplantation for leukemia and other types of cancer. In a paper in the journal Science, available early online Dec.

Preventing A Recurrence Of The Northwick Park Trial
Scientists investigating the 2006 Northwick Park drug-trial disaster that left six healthy volunteers hospitalised say they have developed new pre-clinical tests that could have stopped the trial from ever going ahead. But Dr Stephen Poole, speaking at the British Pharmacological Society's Winter Meeting in Brighton, said that research is still "ongoing" to understand why the drug had such an adverse effect in the clinic but not in pre-clinical testing.

One Step Closer To A Treatment For Mixed-Lineage Leukemia
Infants and adults with the blood cancer mixed-lineage leukemia (MLL) typically have a poor prognosis, and most infants die before their first birthdays. Although there are varying causes of MLL, most cases are caused by a fusion of two genes, the MLL and the AF4 genes. When the MLL gene is fused to the AF4 gene, a potent cancer-causing oncogene is created.

Genta To Appeal FDA Decision On New Drug Application For Genasense(R) In Patients With Chronic Lymphocytic Leukemia
Genta Incorporated (OTCBB: GNTA.OB) announced that the Company has filed an appeal of the recent negative decision by the Food and Drug Administration's (FDA) Office of Oncology Drug Products (OODP) regarding the Company's New Drug Application (NDA) for Genta's lead oncology product, Genasense® (oblimersen sodium) Injection. The NDA proposed the use of Genasense in combination with chemotherapy as treatment for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

An Enzyme That Mutates Antibodies Also Targets A Cancer-Causing Oncogene
The human immune system is in a perpetual state of self-experimentation. It expertly mutates and shuffles the DNA of its own cells to evolve new defenses against the vast array of microbes that try to invade our bodies. But when the genetic experiment goes awry, the result can be a deadly cancer.

Promising Results From Two Trials Highlighting Developmental Oral IMiDS(R) Compound Pomalidomide Presented At The ASH
Celgene International Sarl (Nasdaq: CELG) today announced that its next IMiDs compound, pomalidomide, has shown promising activity with manageable safety and tolerability for the treatment of relapsed/refractory multiple myeloma (MM) and myelofibrosis. The data were presented at the 50th Annual American Society of Hematology meeting in San Francisco, CA.